Auteri G et al. Longer-term response to SARS-CoV-2 vaccine in MPN patients: Role of ruxolitinib and disease severity. Leuk Res 2022;116:106819. Abstract

Gerds AT et al. Determining the recommended dose of pacritinib: Results from the PAC203 dose-finding trial in advanced myelofibrosis. Blood Adv 2020;4(22):5825-35. Abstract

Guglielmelli P et al. Impact of ruxolitinib on survival of patients with myelofibrosis in the real world: Update of the ERNEST Study. Blood Adv 2022;6(2):373-75. Abstract

Harrington P et al. Impaired humoral and T cell response to vaccination against SARS-CoV-2 in chronic myeloproliferative neoplasm patients treated with ruxolitinib. Blood Cancer J 2022;12(4):73. Abstract

Harrison CN et al. Fedratinib in patients with myelofibrosis previously treated with ruxolitinib: An updated analysis of the JAKARTA2 study using stringent criteria for ruxolitinib failure. Am J Hematol 2020;95(6):594-603. Abstract

Palandri et al. Philadelphia-negative chronic myeloproliferative neoplasms during the COVID-19 pandemic: Challenges and future scenarios. Cancers 2021;13(19):4750. Abstract

Pimpinelli F et al. Fifth-week immunogenicity and safety of anti-SARS-CoV-2 BNT162b2 vaccine in patients with multiple myeloma and myeloproliferative malignancies on active treatment: Preliminary data from a single institution. J Hematol Oncol 2021;14:81. Abstract

Venugopal S, Mascarenhas J. The odyssey of pacritinib in myelofibrosis. Blood Adv 2022;6(16):4905-13. Abstract

Waksal WA, Mascarenhas J. Novel therapies in myelofibrosis: Beyond JAK inhibitors. Curr Hematol Malig Rep 2022;17(5):140-54. Abstract